Fluorodeoxyglucose Imaging Studies to Detect Lymphoma

NCT01672918 | Withdrawn

• 2 other identifiers: 12018412-I-0184
• Study Type: observational
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Background: \- Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of the lymph system. People with ALPS often have swollen lymph nodes, especially in the neck and armpit. They also have a much higher risk of developing lymphoma. It is not always easy to determine whether the swollen lymph nodes are caused by ALPS or by lymphoma. Researchers want to see whether different imaging studies can show the difference between ALPS and lymphoma. The studies used will be positron emission tomography (PET) and computed tomography (CT). Researchers will use a drug called fluorodeoxyglucose (FDG) to look at the lymph nodes. Objectives: \- To see how well imaging studies can distinguish between swollen lymph nodes caused by ALPS or by lymphoma. Eligibility:

• Individuals must be 5 years of age or older and enrolled on the National Institutes of Health natural history study of ALPS.
• Participants should either have lymphoma or have symptoms that suggest possible lymphoma. Design:
• Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected.
• Participants will have an FDG-PET/CT scan. It will be performed according to standard procedures.
• If the results of the scan do not show lymphoma, participants will stay on the study for 1 year for clinical follow up. They may have a second FDG-PET/CT scan if there is a change in symptoms. Such changes include further enlargement of lymph nodes, unexplained fevers, or weight loss.
• If the results of the scan show evidence of new or worsening lymphoma, treatment on this study will end. Further tests based on clinical symptoms, including a lymph node biopsy, may be done under the ALPS natural history study to rule out or make a diagnosis of lymphoma.

Conditions

Autoimmune Lymphoproliferative Syndrome; Lymphoma

Keywords

PET/CT; Lymphoma; Lymphadenopathy; ALPS

Eligibility Criteria

• Age: 5 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• To qualify for enrollment, patients must meet all of the following:
• Fulfill current criteria for the diagnosis of ALPS, which includes documented chronic nonmalignant lymphadenopathy and/or splenomegaly, and either greater than or equal to 1.5% T-cell receptor alpha/beta+ DNTs in the peripheral blood or confirmed RAS mutation with or without elevated alpha/beta DNTs.
• Be enrolled in ALPS natural history protocol #93-I-0063.
• Have 1 or more of the following:
• Sudden enlargement of at least 1 lymph node or group of lymph nodes over baseline.
• Systemic symptoms suspicious for lymphoma (i.e., loss of weight, loss of appetite, fatigue, night sweats, fever, and pruritus).
• A histologically proven diagnosis of lymphoma or other malignancy.
• Be 5 years of age or older.

You may not qualify if:

• Patients will be excluded if any of the following is present:
• Concurrent proven infection or inflammatory disease (e.g., sarcoidosis), which itself often shows increased FDG uptake by PET and which could interfere with the interpretation of study results.
• Hyperglycemia (regardless of etiology) determined by fasting glucose of \>200 mg/dL
• Weight in excess of 400 lb, which will exceed the weight limit for the scanner table.
• Pregnancy or breast-feeding. For women of childbearing potential, a negative urine or serum pregnancy test is required within 24 hours prior to an FDG-PET/CT scan.

Sponsors & Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID): lead

Related Publications (3)

• Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y, Fleisher TA, Lim MS, Jaffe ES, Puck JM, Lenardo MJ, Straus SE. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997 Feb 15;89(4):1341-8.

  PMID: 9028957 BACKGROUND

• Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. 1999 Apr 6;130(7):591-601. doi: 10.7326/0003-4819-130-7-199904060-00020.

  PMID: 10189330 BACKGROUND

• Avila NA, Dwyer AJ, Dale JK, Lopatin UA, Sneller MC, Jaffe ES, Puck JM, Straus SE. Autoimmune lymphoproliferative syndrome: a syndrome associated with inherited genetic defects that impair lymphocytic apoptosis--CT and US features. Radiology. 1999 Jul;212(1):257-63. doi: 10.1148/radiology.212.1.r99jl40257.

  PMID: 10405750 BACKGROUND

MeSH Terms

Conditions

Autoimmune Lymphoproliferative Syndrome; Lymphoma; Lymphadenopathy

Condition Hierarchy (Ancestors)

Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Autoimmune Diseases; Immune System Diseases; Immunoproliferative Disorders; Neoplasms by Histologic Type; Neoplasms

Study Officials

• V. Koneti Rao, M.D.

  National Institute of Allergy and Infectious Diseases (NIAID)

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: PROSPECTIVE
• Sponsor Type: NIH
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 23, 2012
• First Posted: August 27, 2012
• Study Start: August 6, 2012
• Study Completion: February 27, 2015
• Last Updated: December 5, 2019

Record last verified: 2015-02-27